A common variant in the adiponectin gene on weight loss and body composition under sibutramine therapy in obesity

Clinical Pharmacology: Advances and Applications

Volumn 2, Issue 1, 2010, Pages 105-110

  Hsiao, Tun Jen ^a   Wu, Lawrence Shih Hsin ^b   Huang, Shih Yi ^a   Lin, Eugene ^b  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b VITA GENOMICS INC   (Taiwan)

Author keywords

Body fat; Obesity; Sibutramine; Single nucleotide polymorphisms; Weight loss

Indexed keywords

ADIPONECTIN; PLACEBO; SIBUTRAMINE;

ADULT; AGED; ARTICLE; BODY COMPOSITION; BODY FAT; CLINICAL ASSESSMENT; DRUG EFFICACY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT REDUCTION;

EID: 77955477553     PISSN: None     EISSN: 11791438     Source Type: Book Series    
DOI: None     Document Type: Article

References (34)

1. Sharma B, Henderson DC. Sibutramine: current status as an anti-obesity drug and its future perspectives. Expert Opin Pharmacother. 2008;9: 2161-2173.
2. Tziomalos K, Krassas GE, Tzotzas T. The use of sibutramine in the management of obesity and related disorders: an update. Vasc Health Risk Manag. 2009;5(1):441-452.
3. Hauner H, Meier M, Jöckel KH, Frey UH, Siffert W. Prediction of successful weight reduction under sibutramine therapy through genotyping of the G-protein beta3 subunit gene (GNB3) C825T polymorphism. Pharmacogenetics. 2003;13:453-459.
4. Vazquez Roque MI, Camilleri M, Clark MM, et al. Alteration of gastric functions and candidate genes associated with weight reduction in response to sibutramine. Clin Gastroenterol Hepatol. 2007;5: 829-837.
5. Grudell AB, Sweetser S, Camilleri M, et al. A controlled pharmacoge-netic trial of sibutramine on weight loss and body composition in obese or overweight adults. Gastroenterology. 2008;135:1142-1154.
6. Hsiao DJ, Wu LS, Huang SY, Lin E. Weight loss and body fat reduction under sibutramine therapy in obesity with the C825T polymorphism in the guanine nucleotide binding protein beta polypeptide 3 gene. Pharmacogenet Genomics. 2009;19(9):730-733.
7. Hsiao TJ, Wu LS, Huang SY, Lin E. Effect of the common G-866A polymorphism of the uncoupling protein 2 gene on weight loss and body composition under sibutramine therapy in an obese Taiwanese population. Mol Diagn Ther. In press 2010.
8. Yang WS, Chuang LM. Human genetics of adiponectin in the metabolic syndrome. J Mol Med. 2006;84:112-121.
9. Valsamakis G, McTernan PG, Chetty R, et al. Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines. Metabolism. 2004;53:430-434.
10. Kim DM, Yoon SJ, Ahn C W, et al. Sibutramine improves fat distribution and insulin resistance, and increases serum adiponectin levels in Korean obese nondiabetic premenopausal women. Diabetes Res Clin Pract. 2004;66 Suppl 1: S139-S144.
11. Stroubini T, Perelas A, Liapi C, et al. Serum adiponectin and resistin in rats under three isocaloric diets: The effect of sibutramine. Cytokine. 2009;46:171-175.
12. Takahashi M, Arita Y, Yamagata K, et al. Genomic structure and mutations in adipose-specific gene, adiponectin. Int J Obes Relat Metab Disord. 2000;24:861-868.
13. Vasseur F, Helbecque N, Dina C, et al. Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the APM1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians. Hum Mol Genet. 2002;11:2607-2614.
14. Populaire C, Mori Y, Dina C, et al. Does the-11377 promoter variant of APM1 gene contribute to the genetic risk for type 2 diabetes mellitus in Japanese families? Diabetologia. 2003;46:443-445.
15. Gu H F, Abulaiti A, Ostenson CG, et al. Single nucleotide polymorphisms in the proximal promoter region of the adiponectin (APM1) gene are associated with type 2 diabetes in Swedish Caucasians. Diabetes. 2004;53:S31-S35.
16. Schwarz PE, Govindarajalu S, Towers W, et al. Haplotypes in the promoter region of the ADIPOQ gene are associated with increased diabetes risk in a German Caucasian population. Horm Metab Res. 2006;38:447-451.
17. Yang M, Qiu CC, Chen W, Xu LL, Yu M, Xiang HD. Identification of a regulatory single nucleotide polymorphism in the adiponectin (APM1) gene associated with type 2 diabetes in Han nationality. Biomed Environ Sci. 2008;21:454-459.
18. Rasmussen-Torvik LJ, Pankow JS, Jacobs DR Jr, Steinberger J, Moran A, Sinaiko AR. The association of SNPs in ADIPOQ, ADIPOR1, and ADIPOR2 with insulin sensitivity in a cohort of adolescents and their parents. Hum Genet. 2009;125:21-28.
19. Wu LS, Hsieh CH, Pei D, Hung YJ, Kuo S W, Lin E. Association and interaction analyses of genetic variants in ADIPOQ, ENPP1, GHSR, PPARgamma and TCF7L2 genes for diabetic nephropathy in a Taiwanese population with type 2 diabetes. Nephrol Dial Transplant. 2009;24(11):3360-3366.
20. Gu H F. Biomarkers of adiponectin: plasma protein variation and genomic DNA polymorphisms. Biomark Insights. 2009;4:123-133.
21. Laumen H, Saningong AD, Heid IM, et al. Functional characterization of promoter variants of the adiponectin gene complemented by epidemiological data. Diabetes. 2009;58(4):984-991.
22. Vasseur F, Helbecque N, Lobbens S, et al. Hypoadiponectinaemia and high risk of type 2 diabetes are associated with adiponectin-encoding (ACDC) gene promoter variants in morbid obesity: evidence for a role of ACDC in diabesity. Diabetologia. 2005;48(5):892-899.
23. Heid IM, Wagner SA, Gohlke H, et al. Genetic architecture of the APM1 gene and its influence on adiponectin plasma levels and parameters of the metabolic syndrome in 1,727 healthy Caucasians. Diabetes. 2006;55(2):375-384.
24. Bouatia-Naji N, Meyre D, Lobbens S, et al. ACDC/adiponectin polymorphisms are associated with severe childhood and adult obesity. Diabetes. 2006;55(2):545-550.
25. Tan CE, Ma S, Wai D, Chew SK, Tai ES. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care. 2004;27: 1182-1186.
26. Lin E, Pei D, Hung YJ, Hsieh CH, Wu LS. Gene-gene interactions among genetic variants from obesity candidate genes for non-obese and obese populations in type 2 diabetes. Genet Test Mol Biomarkers. 2009;13(4):485-493.
27. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006;116:1784-1792.
28. Zhang D, Ma J, Brismar K, Efendic S, Gu H F. A single nucleotide polymorphism alters the sequence of SP1 binding site in the adiponectin promoter region and is associated with diabetic nephropathy among type 1 diabetic patients in the Genetics of Kidneys in Diabetes Study. J Diabetes Complications. 2009;23(4):265-272.
29. Yang WS, Lee WJ, Funahashi T, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab. 2001;86:3815-3819.
30. Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes. 2003;52:1779-1785.
31. Whitehead J P, Richards AA, Hickman IJ, Macdonald GA, Prins JB. Adiponectin-a key adipokine in the metabolic syndrome. Diabetes Obes Metab. 2006;8:264-280.
32. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7:941-946.
33. The International HapMap Consortium. The international HapMap project. Nature. 2003;426:789-794.
34. Peters WR, MacMurry J P, Walker J, Giese RJ Jr, Comings DE. Phenylethanolamine N-methyltransferase G-148A genetic variant and weight loss in obese women. Obes Res. 2003;11(3):415-419.